Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Short term Debt (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Short term Debt for 8 consecutive years, with $370000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Short term Debt changed N/A year-over-year to $370000.0, compared with a TTM value of $370000.0 through Jun 2025, changed N/A, and an annual FY2024 reading of $360000.0, changed N/A over the prior year.
  • Short term Debt was $370000.0 for Q2 2025 at Avalo Therapeutics, up from $360000.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $370000.0 in Q2 2025 and bottomed at $360000.0 in Q4 2024.